CompanyBBIONasdaqPalo Alto, CA

BridgeBio Pharma, Inc.

BridgeBio Pharma develops medicines for genetic conditions across multiple therapeutic programs using its hub-and-spoke organizational model.

SEC EDGAR ClinicalTrials.gov bridgebio.com

8-KAug 31Latest SEC filing, period to Aug 31

Aug 17Latest story

August 2026

BridgeBio secondary offering by KKR Genetic Disorder L.P. priced at $78.00 per share

Aug 17FinancingBridgeBio Pharma, Inc.

BridgeBio reports Q2 2026 results as all three pipeline NDAs reach FDA review

Aug 10Quarterly updateBridgeBio Pharma, Inc.

July 2026

FDA accepts BridgeBio's NDA for encaleret in ADH1

Jul 22Regulatory milestoneBridgeBio Pharma, Inc.

BridgeBio secures $1 billion preferred equity deal led by Sixth Street

Jul 2FinancingBridgeBio Pharma, Inc.